Form 4: Avanos Medical Executive John Hurley Reports Acquisition of Common Stock

Sentiment:

SEC Form 4 Filing


John Hurley, Principal Accounting Officer of Avanos Medical, reports acquiring 1,961 shares of common stock through time-based restricted share units.

Summary

  • On March 7, 2025, John Hurley, Principal Accounting Officer of Avanos Medical, acquired 1,961 shares of common stock.
  • The acquisition was through time-based restricted share units (TRSUs) awarded under the company's 2021 Long Term Incentive Plan, as amended.
  • These TRSUs will vest in three equal installments: 1/3 on March 7, 2026, 1/3 on March 7, 2027, and 1/3 on March 7, 2028.
  • Following the transaction, Hurley directly owns 11,709 shares of Avanos Medical common stock.
  • Each TRSU is the economic equivalent of one share of Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by an executive, indicating alignment with company goals but not necessarily a strong positive or negative signal.

Positives

  • The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the TRSUs (1/3 on March 7, 2026, 1/3 on March 7, 2027, and 1/3 on March 7, 2028) suggests a long-term incentive plan for the executive.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

  • Executive compensation packages including restricted stock units are a common practice among publicly traded companies, particularly in the healthcare and medical device industries.
  • Companies like Medtronic, Stryker, and Johnson & Johnson also utilize similar long-term incentive plans to retain and motivate key executives.
  • The vesting schedules and terms of these plans are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

  • The increased stock ownership by a key executive could positively influence investor confidence.

Key Dates

DateDescription
03/07/2025Date of transaction: Acquisition of 1,961 shares of common stock.
03/07/2026First vesting date for 1/3 of the TRSUs.
03/07/2027Second vesting date for 1/3 of the TRSUs.
03/07/2028Final vesting date for 1/3 of the TRSUs.
03/11/2025Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.